Emerging patent landscape for non-viral vectors used for gene therapy
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical trials have been initiated for non-infectious uveitis (NIU) disease of the eye using naked DNA delivery.
“Clinical trials have been initiated for non-infectious uveitis (NIU) disease of the eye using naked DNA delivery.”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [42]
The clinical grade plasmid pEYS606 currently in the clinical trial is electro-transferred to the ciliary muscle of the eye.
“The clinical grade plasmid pEYS606 currently in the clinical trial is electro-transferred to the ciliary muscle of the eye [42,43].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 13 · Cited by 88
- Authors
- Picanço-Castro, V., Pereira, C. G., Covas, D. T., Porto, G. S., Athanassiadou, A., & Figueiredo, M. L.
- Affiliations
- Universidade de São Paulo (BR)
- University of Patras (GR)
- Purdue University West Lafayette (US)
- Corresponding author
- Figueiredo, Marxa Leão
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2020-02
- Volume
- 38
- Issue
- 2
- Pages
- 151-157
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC7308177
- OpenAlex
- W3004682895
- Cited by
- 88
- References
- 13
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 14 · 2023: 13 · 2022: 14 · 2021: 18 · 2020: 6
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA196947)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR069079)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Intellectual Property and Patents
- Keywords
- non-viral vectors, gene therapy, patent landscape, intellectual property, gene delivery
- MeSH terms
- Animals, Genetic Vectors, Humans, Patents as Topic, Publications, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
